These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 10423172)
1. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development. Phillips RM Biochem Pharmacol; 1999 Jul; 58(2):303-10. PubMed ID: 10423172 [TBL] [Abstract][Full Text] [Related]
2. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. Fitzsimmons SA; Workman P; Grever M; Paull K; Camalier R; Lewis AD J Natl Cancer Inst; 1996 Mar; 88(5):259-69. PubMed ID: 8614004 [TBL] [Abstract][Full Text] [Related]
3. Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4, 7-dione] prop-beta-en-alpha-ol (EO9) by human DT-diaphorase. Phillips RM Biochem Pharmacol; 1996 Dec; 52(11):1711-8. PubMed ID: 8986133 [TBL] [Abstract][Full Text] [Related]
4. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Cliffe S; Taylor ML; Rutland M; Baguley BC; Hill RP; Wilson WR Int J Radiat Oncol Biol Phys; 1994 May; 29(2):373-7. PubMed ID: 8195036 [TBL] [Abstract][Full Text] [Related]
5. DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. Plumb JA; Gerritsen M; Workman P Br J Cancer; 1994 Dec; 70(6):1136-43. PubMed ID: 7526885 [TBL] [Abstract][Full Text] [Related]
6. The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Walton MI; Smith PJ; Workman P Cancer Commun; 1991 Jul; 3(7):199-206. PubMed ID: 1714284 [TBL] [Abstract][Full Text] [Related]
7. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. Zhou S; Kestell P; Baguley BC; Paxton JW Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491 [TBL] [Abstract][Full Text] [Related]
8. Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9. Bailey SM; Wyatt MD; Friedlos F; Hartley JA; Knox RJ; Lewis AD; Workman P Br J Cancer; 1997; 76(12):1596-603. PubMed ID: 9413948 [TBL] [Abstract][Full Text] [Related]
9. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase. Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423 [TBL] [Abstract][Full Text] [Related]
10. Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9. Smitskamp-Wilms E; Hendriks HR; Peters GJ Gen Pharmacol; 1996 Apr; 27(3):421-9. PubMed ID: 8723519 [TBL] [Abstract][Full Text] [Related]
11. [DT-diaphorase]. Mikami K; Shirakusa T; Tsuruo T Gan To Kagaku Ryoho; 1997 Sep; 24(11):1606-10. PubMed ID: 9309161 [TBL] [Abstract][Full Text] [Related]
12. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. Plumb JA; Gerritsen M; Milroy R; Thomson P; Workman P Int J Radiat Oncol Biol Phys; 1994 May; 29(2):295-9. PubMed ID: 8195022 [TBL] [Abstract][Full Text] [Related]
13. Induction of DT-diaphorase by 1,2-dithiole-3-thione and increase of antitumour activity of bioreductive agents. Begleiter A; Leith MK; Curphey TJ Br J Cancer Suppl; 1996 Jul; 27():S9-14. PubMed ID: 8763837 [TBL] [Abstract][Full Text] [Related]
14. Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones. Gustafson DL; Beall HD; Bolton EM; Ross D; Waldren CA Mol Pharmacol; 1996 Oct; 50(4):728-35. PubMed ID: 8863816 [TBL] [Abstract][Full Text] [Related]
15. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Lash CJ; Li AE; Rutland M; Baguley BC; Zwi LJ; Wilson WR Br J Cancer; 1998 Aug; 78(4):439-45. PubMed ID: 9716024 [TBL] [Abstract][Full Text] [Related]
16. Induction of STAT and NFkappaB activation by the antitumor agents 5,6-dimethylxanthenone-4-acetic acid and flavone acetic acid in a murine macrophage cell line. Ching LM; Young HA; Eberly K; Yu CR Biochem Pharmacol; 1999 Oct; 58(7):1173-81. PubMed ID: 10484075 [TBL] [Abstract][Full Text] [Related]
17. Bioreductive activation of a series of indolequinones by human DT-diaphorase: structure-activity relationships. Phillips RM; Naylor MA; Jaffar M; Doughty SW; Everett SA; Breen AG; Choudry GA; Stratford IJ J Med Chem; 1999 Oct; 42(20):4071-80. PubMed ID: 10514277 [TBL] [Abstract][Full Text] [Related]
18. Induction of DT-diaphorase by 1,2-dithiole-3-thiones in human tumour and normal cells and effect on anti-tumour activity of bioreductive agents. Doherty GP; Leith MK; Wang X; Curphey TJ; Begleiter A Br J Cancer; 1998 Apr; 77(8):1241-52. PubMed ID: 9579829 [TBL] [Abstract][Full Text] [Related]
19. The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase? Robertson N; Stratford IJ; Houlbrook S; Carmichael J; Adams GE Biochem Pharmacol; 1992 Aug; 44(3):409-12. PubMed ID: 1510692 [TBL] [Abstract][Full Text] [Related]
20. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes. Chen S; Knox R; Lewis AD; Friedlos F; Workman P; Deng PS; Fung M; Ebenstein D; Wu K; Tsai TM Mol Pharmacol; 1995 May; 47(5):934-9. PubMed ID: 7746280 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]